Cyclopharm has secured a multi-site agreement with Northwestern Medicine, marking a major expansion into Chicago’s healthcare market and reinforcing its US growth strategy.
- Multi-site Technegas® agreement with Northwestern Medicine covering seven sites
- Immediate installation at Northwestern Memorial Hospital, Chicago
- Strategic entry into a major US healthcare market with potential for broader Midwest expansion
- Recurring revenue model through consumables and service fees
- Follows prior multi-site deal with University of Pennsylvania Health System
Cyclopharm’s Chicago Breakthrough
Cyclopharm Limited (ASX:CYC) has taken a significant step forward in its US commercial rollout by securing a multi-site agreement with Northwestern Medicine, a prestigious academic health system based in Chicago. The deal includes an immediate installation of Cyclopharm’s Technegas® technology at Northwestern Memorial Hospital, one of the nation’s top-ranked hospitals, with the potential for up to six additional installations across the broader Northwestern Medicine network.
This agreement represents more than just a new customer; it establishes a critical foothold in one of the largest and most strategically important healthcare markets in the United States. Chicago’s healthcare ecosystem is known for its scale and influence, making this a valuable lighthouse win for Cyclopharm’s ambitions in the Midwest.
Strategic and Financial Implications
The deal aligns closely with Cyclopharm’s strategy of embedding Technegas® within leading academic and research-driven health systems. Northwestern Medicine’s reputation for clinical excellence and innovation offers Cyclopharm a platform to showcase its technology’s benefits, potentially accelerating adoption across the network’s seven sites.
Financially, the agreement supports Cyclopharm’s recurring revenue model. Each Technegas® installation generates ongoing income from consumables used per patient procedure, alongside annual service and support fees. This model not only provides steady revenue but also scales with patient volumes, underpinning sustainable growth.
Building on US Momentum
This announcement follows Cyclopharm’s earlier multi-site agreement with the University of Pennsylvania Health System, which covers 11 clinical locations. Together, these deals demonstrate accelerating execution of Cyclopharm’s US strategy, focused on establishing leading reference sites, building regional density, and expanding across integrated healthcare networks.
CEO James McBrayer highlighted the importance of the Northwestern Medicine agreement, noting it as a “significant milestone” that provides a “critical foothold” in a major US market. The combination of initial installations with contracted pathways to multiple sites is central to driving scalable and recurring revenue growth in the US.
Looking Ahead
While the initial installation is confirmed, the timeline and certainty of the additional six site installations remain to be seen. Investors will be watching closely for updates on rollout progress and revenue recognition from these sites. The deal also raises expectations for further expansion across other major US healthcare systems, as Cyclopharm continues to build its footprint and validate Technegas® as a standard in functional lung imaging.
Bottom Line?
Cyclopharm’s Northwestern Medicine deal cements its Midwest presence, setting the stage for broader US growth and recurring revenue streams.
Questions in the middle?
- What is the expected timeline for the additional six Technegas® installations across Northwestern Medicine?
- How will Cyclopharm manage competition and adoption challenges in the broader US healthcare market?
- What impact will these US expansions have on Cyclopharm’s overall revenue and profitability in the near term?